A randomized, controlled, blinded human trial of GHK-Cu monotherapy, with a vehicle-only control (and a needling-plus-vehicle arm if a procedure is used), objective endpoints such as blinded global photography and target-area hair counts over at least several months, adequate statistical power, pre-registration, and independent replication
Limited data available suggests that dose adjustment of Vitneurin AQ Injection may not be needed in these patients
Why choose Tower Urology for peptide therapy near you
Label administration requires an empty stomach, no more than 4 oz of plain water, and a 30-minute wait before food, drink, or other oral medication
The shift of these specific peptides to Category 2 is a pivotal moment in regenerative medicine